LSU Health research discovers potential new Rx target for AMD and Alzheimer's

November 11, 2019

New Orleans, LA - Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine, found a new mechanism by which a class of molecules his lab discovered may protect brain and retinal cells against neurodegenerative diseases like age-related macular degeneration and Alzheimer's. Results, published online in PNAS, identify elovanoids as a potential new therapeutic approach for these devastating conditions.

"It is the first report that elovanoids are potential senolytic therapies because they target and dramatically arrest gene expression engaged in cell disturbances, including senescence gene programs and retina cell death in conditions that recapitulate retinal degenerative diseases," notes Dr. Bazan, who also hold the Ernest C. and Yvette C. Villere Chair of Retinal Degenerative Diseases at LSU Health New Orleans. "Since the retina is key in age-related macular degeneration and is an integral part of the nervous system, the reported discoveries are also applicable to Alzheimer's disease and other neurodegenerative conditions."

As humans age, cells gradually function more sluggishly and eventually become senescent, losing their ability to divide and renew. While senescence can be beneficial earlier in life by among other things, aiding wound healing and preventing tumor development, at older ages, tissues become littered with these dysfunctional cells, which then attract inflammatory immune cells. Along with accumulations of the toxic protein, Amyloid beta in brain and retinal tissues, the resultant chronic inflammation can lead to brain and photoreceptor cell death and the development of neurodegenerative diseases.

In experimental models of age-related macular degeneration (AMD) and Alzheimer's disease, Bazan's team found that elovanoids (bioactive chemical messengers made from omega-3 very long-chain polyunsaturated fatty acids) counteracted these processes. These novel compounds target senescence genes, a key senescence protein, and the expression of senescence-related genes in the retinal pigment epithelial cells. Elovanoids also restored the structure and integrity of both the retinal epithelial and photoreceptor cells after being damaged by amyloid beta. Overall, they foster repair, remodeling and regeneration.

"We demonstrate in the paper that the elovanoids block these events and foster the survival and function of these cells," Bazan adds. The incidence of blinding retinal diseases and cognitive-decline is rising due to longer life expectancy. The magnitude of these illnesses is exacerbated since the consequences of several neurological conditions could set in motion dementia-like states such as stroke, traumatic brain injury, etc.

Although the paper shows that elovanoids are protective for retina and likely brain as well, Bazan cautions that "further research is needed, particularly by using these models to define the intimacy of the gene transcription of senescence and the epigenomic implications of these findings." He reasons that his lab is now "poised to define further novel unifying regulatory mechanisms that sustain health span during aging and neurodegenerative diseases."

Besides Bazan, other members of the LSU Health New Orleans Neuroscience Center research team include Khanh V. Do and Drs. Marie-Audrey I. Kautzmann, Bokkyoo Jun and William C. Gordon. Robert Nshimiyimana, Rong Yang and Nicos A. Petasis from the University of Southern California, Los Angeles, also participated.

This study was supported by the National Institutes of Health/National Eye Institute grant R01 EY005121 and the Eye Ear Nose & Throat Foundation.

"A challenge of civilization is to slow down age-related decline and to be able to maintain quality of life, successful aging if you will," Bazan concludes.
-end-
LSU Health Sciences Center New Orleans (LSU Health New Orleans) educates Louisiana's health care professionals. The state's health sciences university leader, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research, the LSU Health New Orleans research enterprise generates jobs and enormous annual economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu, http://www.twitter.com/LSUHealthNO, or http://www.facebook.com/LSUHSC.

Louisiana State University Health Sciences Center

Related Traumatic Brain Injury Articles from Brightsurf:

Point-of-care biomarker assay for traumatic brain injury
Intracranial abnormalities on CT scan in patients with traumatic brain injury (TBI) can be predicted by glial fibrillary acidic protein (GFAP) levels in the blood.

Long-studied protein could be a measure of traumatic brain injury
WRAIR scientists have recently demonstrated that cathepsin B, a well-studied protein important to brain development and function, can be used as biomarker, or indicator of severity, for TBI.

Reducing dangerous swelling in traumatic brain injury
After a traumatic brain injury (TBI), the most harmful damage is caused by secondary swelling of the brain compressed inside the skull.

Blue light can help heal mild traumatic brain injury
Daily exposure to blue wavelength light each morning helps to re-entrain the circadian rhythm so that people get better, more regular sleep which was translated into improvements in cognitive function, reduced daytime sleepiness and actual brain repair.

Dealing a therapeutic counterblow to traumatic brain injury
A team of NJIT biomedical engineers are developing a therapy which shows early indications it can protect neurons and stimulate the regrowth of blood vessels in damaged tissue.

Predictors of cognitive recovery following mild to severe traumatic brain injury
Researchers have shown that higher intelligence and younger age are predictors of greater cognitive recovery 2-5 years post-mild to severe traumatic brain injury (TBI).

Which car crashes cause traumatic brain injury?
Motor vehicle crashes are one of the most common causes of TBI-related emergency room visits, hospitalizations and deaths.

Traumatic brain injury and kids: New treatment guidelines issued
To help promote the highest standards of care, and improve the overall rates of survival and recovery following TBI, a panel of pediatric critical care, neurosurgery and other pediatric experts today issued the third edition of the Brain Trauma Foundation Guidelines for the Management of Pediatric Severe TBI.

Addressing sleep disorders after traumatic brain injury
Amsterdam, NL, December 10, 2018 - Disorders of sleep are some of the most common problems experienced by patients after traumatic brain injury (TBI).

Rutgers researchers discover possible cause for Alzheimer's and traumatic brain injury
Rutgers researchers discover a possible cause for Alzheimer's and traumatic brain injury, and the new mechanism may have also led to the discovery of an effective treatment.

Read More: Traumatic Brain Injury News and Traumatic Brain Injury Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.